The Future of Bispecifics & CAR-T Therapy

Safety Considerations as CAR-T and Bispecifics Expand in Use

Sequencing CAR-T vs. Bispecifics

Adopting BOSS in Community Practice

Selecting Candidates for Outpatient Step-Up Dosing

Outpatient Step-Up Dosing: Safe, Feasible & Scalable

BOSS Program: Standardizing Safe Outpatient Bispecific Step-Up Dosing

Bispecifics Move to Second Line: What the Shift Means in Practice

Breaking Down Bispecific Antibodies

A Career Path Shaped by Myeloma's Collaborative Spirit & Rapid Discovery

Introduction: Dr. Diana Cirstea, Medical Oncologist at Mass General Brigham Cancer Institute